Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medilac-S
- Development stage
- Phase 4
- Lead developer
- Lallemand Health Solutions
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Medilac-S is a probiotic pharmaceutical product containing a combination of live bacteria, specifically *Bacillus subtilis* (strain R-179) and *Enterococcus faecium* (strain R-026). Developed and manufactured by Hanmi Pharmaceutical, it is primarily indicated for the treatment of gastrointestinal disorders including diarrhea, constipation, and dyspepsia resulting from intestinal flora imbalance. The mechanism of action involves the colonization of the gut by beneficial bacteria, which compete with and inhibit the growth of pathogenic microorganisms, produce essential B vitamins, and secrete enzymes that aid digestion. It is also frequently used to prevent or treat antibiotic-associated diarrhea by replenishing the natural microbial population of the digestive tract.
- Brand names
- Medilac-S
- Other names
- Medilac-VitaBacillus subtilis and Enterococcus faecium probiotic
Beyond the preview
Go deeper on Medilac-S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medilac-S.